Xiangxue Pharmaceutical Co.,Ltd. (SHE:300147)

China flag China · Delayed Price · Currency is CNY
9.41
-0.09 (-0.95%)
Apr 28, 2026, 3:54 PM CST
57.62%
Market Cap 6.22B
Revenue (ttm) 1.60B
Net Income (ttm) -1.39B
Shares Out 661.28M
EPS (ttm) -2.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 13,134,746
Average Volume 18,812,254
Open 10.18
Previous Close 9.50
Day's Range 9.29 - 10.18
52-Week Range 5.52 - 12.79
Beta 0.57
RSI 43.92
Earnings Date Apr 29, 2026

About Xiangxue Pharmaceutical

Xiangxue Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of modern Chinese medicine in China. The company provides ban lan gen granules, flu-over liquid, juhong cough-off liquid, and juhong cough-off decoction; chinese herbal, such as huazhou citri grandis, goji berry, chrysanthemum, and rose dried buds; beverages, including king sarsae, asia sarsae, diet sarsae, juice soda, soymilk, coconut juice, and fruit enzyme; and antiviral oral liquids under the Xiangxue brand name. It also provides medical devices... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1986
Employees 2,769
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300147
Full Company Profile

Financial Performance

In 2025, Xiangxue Pharmaceutical's revenue was 1.60 billion, a decrease of -14.16% compared to the previous year's 1.86 billion. Losses were -1.39 billion, 62.2% more than in 2024.

Financial Statements

News

There is no news available yet.